Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 30;16(1):192.
doi: 10.3390/cancers16010192.

A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety

Mara Mantiero  1 , Marta Bini  2 , Maggie Polignano  1 , Luca Porcu  3 , Roberta Sanfilippo  2 , Chiara Fabbroni  2 , Gabriella Parma  4 , Mariateresa Lapresa  4 , Carmelo Calidona  4   5 , Cecilia Silvestri  2 , Andrea Franza  2 , Francesco Raspagliesi  1 , Nicoletta Colombo  4   6 , Monika Ducceschi  1
Affiliations

A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety

Mara Mantiero et al. Cancers (Basel). .

Abstract

Background: Uterine leiomyosarcoma (uLMS) is characterized by aggressive behavior associated with a high risk of relapse and mortality. Several therapeutic agents have been employed in the treatment of metastatic disease, with a poor objective response rate. Pazopanib, approved in 2012, is a multi-targeted, orally active small molecule that exerts its effects by inhibiting several tyrosine kinases. To date, poor research on real-life data has been conducted. We aimed to assess the effectiveness and safety of the drug in everyday clinical practice.

Methods: We present results of multicenter retrospective data on 38 patients with heavily pretreated metastatic uLMS who underwent oral pazopanib during their therapeutic journey.

Results: At a median follow-up of 8.6 months, the disease control rate was 55.2%, with 17% partial responses and 15 patients (39.5%) with stable disease. At a median follow-up of 8.6 months, median progression-free survival was 4 months, and median overall survival was 19.8 months. The most common grade 3 adverse events (AEs) drug-related were hepatic toxicities, diarrhea, hypertension, nausea, and vomiting (all of them with an incidence of 5% considering the whole study cohort). No grade 4 AEs occurred.

Conclusions: Pazopanib in everyday clinical practice is safe and shows a good disease control rate with prolonged survival.

Keywords: effectiveness; pazopanib; safety; survival; uterine leyomiosarcoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curve for progression-free survival.
Figure 2
Figure 2
Kaplan–Meier curves for overall survival.
See this image and copyright information in PMC

References

    1. Ferrandina G., Aristei C., Biondetti P.R., Cananzi F.C.M., Casali P., Ciccarone F., Colombo N., Comandone A., Corvo’ R., De Iaco P., et al. Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa’ italiana di Ginecologia E Ostetricia) Eur. J. Cancer. 2020;139:149–168. doi: 10.1016/j.ejca.2020.08.016. - DOI - PubMed
    1. D’Angelo E., Prat J. Uterine sarcomas: A review. Gynecol. Oncol. 2010;116:131–139. doi: 10.1016/j.ygyno.2009.09.023. - DOI - PubMed
    1. Roberts M.E., Aynardi J.T., Chu C.S. Uterine leiomyosarcoma: A review of the literature and update on management options. Gynecol. Oncol. 2018;151:562–572. doi: 10.1016/j.ygyno.2018.09.010. - DOI - PubMed
    1. Prat J. FIGO staging for uterine sarcomas. Int. J. Gynaecol. Obstet. 2009;104:177–178. doi: 10.1016/j.ijgo.2008.12.008. - DOI - PubMed
    1. Giuntoli R.L., 2nd, Metzinger D.S., DiMarco C.S., Cha S.S., Sloan J.A., Keeney G.L., Gostout B.S. Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy. Gynecol. Oncol. 2003;89:460–469. doi: 10.1016/S0090-8258(03)00137-9. - DOI - PubMed

LinkOut - more resources